

References

- Affolter VK & Moore PF. (2000a) Canine cutaneous and systemic histiocytosis: reactive histiocytosis of dermal dendritic cells. *American Journal of Dermatopathology* 22(1):40–48.
- Affolter VK & Moore P. (2000b) Canine cutaneous histiocytic diseases. In: Bonagura JD, ed. *Kirk's Current Veterinary Therapy XIII: Small Animal Practice*. Philadelphia, PA: W.B. Saunders, p588–91.
- Affolter VK & Moore PF. (2002) Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs. *Veterinary Pathology* 39:74-83.
- Allison RW, Brunner JD, Breshears MA, et al. (2008) Dendritic cell leukaemia in a Golden Retriever. *Veterinary Clinical Pathology* 37(2):190–197.
- Cannon C, Borgatti A, Henson M & Husbands B. (2015) Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma. *Journal of Small Animal Practice*. 56(7), 425-9.
- Craig LE, Julian ME & Ferracone JD. (2002) The diagnosis and prognosis of synovial tumours in dogs: 35 cases. *Veterinary Pathology* 39(1):66–73.
- Dervisis NG, Kiupel M, Qin Q & Cesario L. (2017) Clinical prognostic factors in canine histiocytic sarcoma. *Veterinary Comparative Oncology*. 15(4), 1171-1180.
- Faller M, Lamm C, Affolter VK, et al. (2016) Retrospective characterisation of solitary cutaneous histiocytoma with lymph node metastasis in eight dogs. *Journal of Small Animal Practice*, 57(10), 548-552.
- Kato Y, Murakami M, Hoshino Y, et al. (2013). The Class A Macrophage Scavenger Receptor CD204 is a Useful Immunohistochemical Marker of Canine Histiocytic Sarcoma. *Journal of Comparative Pathology* 148(2-3), 188–196.
- Kezer KA, Barber LG & Jennings SH (2018) Efficacy of dacarbazine as a rescue agent for histiocytic sarcoma in dogs. *Veterinary Comparative Oncology*. 16(1), 77-80
- Klahn SL, Kitchell BE & Dervisis NG. (2011) Evaluation and comparison of outcomes in dogs with periarticular and nonperiarticular histiocytic sarcoma. *Journal of the American Veterinary Medical Association* 239(1):90–96.
- Lenz JA, Furrow E, Craig LE & Cannon CM. (2017) Histiocytic sarcoma in 14 miniature schnauzers - a new breed predisposition? *Journal of Small Animal Practice* 58(8), 461-467.

Manor EK, Craig LE, Sun X & Cannon CM. (2018) Prior joint disease is associated with increased risk of periarticular histiocytic sarcoma in dogs. *Veterinary Comparative Oncology*. 16(1), E83-E88

Mariani CL, Jennings MK, Olby NJ, et al (2015). Histiocytic sarcoma with central nervous system involvement in dogs: 19 cases (2006-2012). *Journal of Veterinary Internal Medicine*. 29(2), 607-13.

Mason SL, Finotello R. & Blackwood L. (2018) Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy. *Veterinary Comparative Oncology*. 16(1), E30-E37

Moore PF & Affolter VK. (2005) Canine and feline histiocytic diseases. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine. St Louis: Elsevier Saunders; p779-782.

Moore PF (2004). The histiocytic disease complex, in Proceedings. Am Coll Vet Intern Med Annu Mtg

Moore PF, Affolter VK & Vernau W. (2006) Canine hemophagocytic histiocytic sarcoma: a proliferative disorder of CD11d⁺ macrophages. *Veterinary Pathology* 43(5):632-645.

Moore PF. (2014). A Review of Histiocytic Diseases of Dogs and Cats. *Veterinary Pathology* 51(1), 167-184.

Nfon CK, Dawson H, Toka FN, et al. (2008) Langerhans cells in porcine skin. *Veterinary Immunology & Immunopathology* 126(3-4):236-247.

Padgett GA, Madewell BR, Keller ET, Jodar L and Packard M (1995) Inheritance of histiocytosis in Bernese mountain dogs. *Journal of Small Animal Practice* 36, 93-8.

Pierezan F, Mansell J, Ambrus A & Hoffmann AR. (2014). Immunohistochemical Expression of Ionized Calcium Binding Adapter Molecule 1 in Cutaneous Histiocytic Proliferative, Neoplastic and Inflammatory Disorders of Dogs and Cats. *Journal of Comparative Pathology* 151(4), 347-351.

Poirier VJ, Hershey AE, Burgess KE, et al. (2014) Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumours. *Journal of Veterinary Internal Medicine* 18:219-222.

Rassnick KM, Moore AS, Russell DS, et al. (2010). Phase II, Open-Label Trial of Single-Agent CCNU in Dogs with Previously Untreated Histiocytic Sarcoma. *Journal of Veterinary Internal Medicine* 24(6), 1528–1531.

Rossi S, Gelain ME & Comazzi S. (2009) Disseminated histiocytic sarcoma with peripheral blood involvement in a Bernese Mountain Dog. *Veterinary Clinical Pathology* 38(1):126–130.

Schultz RM, Puchalski SM, Kent M, et al. (2007) Skeletal lesions of histiocytic sarcoma in nineteen dogs. *Veterinary Radiology & Ultrasound* 48(6):539–543.

Scott DW, Miller WH & Griffin CE. (2001) Neoplastic and Non-neoplastic tumours. In: *Small Animal Dermatology*, 6th edn. Philadelphia, PA: Saunders, p1352–4.

Skorupski KA, Clifford CA, Paoloni MC, et al. (2007) CCNU for the treatment of dogs with histiocytic sarcoma. *Journal of Veterinary Internal Medicine* 21(1):121–126.

Skorupski KA, Rodriguez CO, Krick EL, et al. (2009). Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy. *Veterinary and Comparative Oncology*, 7(2), 139–144.

Thamm DH, Rose B, Kow K, et al. (2012). Masitinib as a chemosensitizer of canine tumour cell lines: A proof of concept study. *The Veterinary Journal* 191(1), 131–134.

Wouda, R. M., Miller, M. E., Chon, E., & Stein, T. J. (2015). Clinical effects of vinorelbine administration in the management of various malignant tumour types in dogs: 58 cases (1997–2012). *Journal of the American Veterinary Medical Association*, 246(11), 1230–1237.